{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-051050","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.878457+00:00","generated_at":"2026-05-21T00:00:30.626661+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Theravance Biopharma holds 2025 annual meeting, elects directors, ratifies auditor, approves say-on-pay","bullets":["Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.","Ratification of Ernst & Young as auditor for FY2025 approved: 45,165,816 for, 578,070 against.","Advisory say-on-pay resolution approved: 30,154,992 for, 374,257 against, 9,536,311 abstain.","Quorum of 45,746,079 shares (91.5% outstanding) present at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-051050","json":"https://secwatch.observer/filing/0001104659-25-051050.json","markdown":"https://secwatch.observer/filing/0001104659-25-051050.md","text":"https://secwatch.observer/filing/0001104659-25-051050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925051050/0001104659-25-051050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925051050/tm2515715d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:00:30.626661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}